Health
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple – Mirage News
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the…
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data is published today in Cancer Research, a journal of the American Associat…
-
Noosa News17 hours agoQueensland teachers strike for second time this year after rejecting 8 per cent wage rise
-
General22 hours agoKim Nok-wan sentenced to life in prison for sexual abuse and exploitation of hundreds of people in South Korea
-
General24 hours agoKangaroos star Ash Riddell wins AFLW best and fairest award
-
General17 hours agoVictorian government blocked fire service from pursuing US giant over PFAS contamination